Analyst Reco. Singular Genomics Systems, Inc.

Equities

OMIC

US82933R1005

Delayed Nasdaq Other stock markets 09:55:07 2024-06-04 am EDT			5-day change	1st Jan Change
0.3658 ^USD	-2.45%		-2.45%	-20.50%

May. 15	Goldman Sachs Trims Price Target on Singular Genomics Systems to $0.75 From $0.85, Maintains Neutral Rating	MT
May. 14	Transcript : Singular Genomics Systems, Inc., Q1 2024 Earnings Call, May 14, 2024

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Goldman Sachs Trims Price Target on Singular Genomics Systems to $0.75 From $0.85, Maintains Neutral Rating	May. 15	MT
UBS Adjusts Singular Genomics Systems Price Target to $0.50 From $0.40, Maintains Neutral Rating	Mar. 20	MT
Goldman Sachs Trims Price Target on Singular Genomics Systems to $0.85 From $0.95, Maintains Neutral Rating	Jan. 22	MT
UBS Adjusts Singular Genomics Systems Price Target to $0.40 From $0.90, Maintains Neutral Rating	23-10-12	MT
UBS Adjusts Singular Genomics Systems Price Target to $0.90 From $1, Maintains Neutral Rating	23-08-10	MT
Goldman Sachs Adjusts Price Target on Singular Genomics Systems to $1 From $1.15, Maintains Neutral Rating	23-08-10	MT
UBS Adjusts Price Target on Singular Genomics Systems to $1 From $1.25, Maintains Neutral Rating	23-07-10	MT
UBS Adjusts Singular Genomics Systems Price Target to $1.25 From $2.25, Maintains Neutral Rating	23-05-10	MT
UBS Adjusts Singular Genomics Systems Price Target to $2.25 From $2.50, Maintains Neutral Rating	23-03-06	MT
Goldman Sachs Adjusts Price Target on Singular Genomics Systems to $3 From $3.50, Maintains Neutral Rating	22-11-08	MT
UBS Adjusts Singular Genomics Systems Price Target to $2.50 From $4.50, Maintains Neutral Rating	22-11-08	MT
UBS Downgrades Singular Genomics Systems to Neutral From Buy, Adjusts Price Target to $4.50 From $10	22-08-17	MT
JPMorgan Downgrades Singular Genomics Systems to Neutral From Overweight	22-08-10	MT
BofA Securities Double Downgrades Singular Genomics Systems to Underperform From Buy; Price Target is $3	22-08-10	MT
Goldman Sachs Downgrades Singular Genomics Systems to Neutral From Buy; Price Target is $3.50	22-08-10	MT
Goldman Sachs Adjusts Singular Genomics Systems Price Target to $5 From $9.50, Maintains Buy Rating	22-07-14	MT
UBS Adjusts Singular Genomics Systems Price Target to $10 From $15, Maintains Buy Rating	22-05-12	MT
Goldman Sachs Adjusts Singular Genomics Systems Price Target to $9.50 From $11, Maintains Buy Rating	22-05-11	MT
Goldman Sachs Adjusts Singular Genomics Systems' Price Target to $11 from $17, Keeps Buy Rating	22-04-13	MT
UBS Adjusts Singular Genomics Systems Price Target to $15 From $25, Maintains Buy Rating	22-03-03	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Singular Genomics Systems, Inc.

Equities

OMIC

US82933R1005

Analyst Reco.

Filters